Search company, investor...

Healios K.K.

healios.co.jp

Stage

Unattributed | Alive

Total Raised

$30.6M

Last Raised

$30.6M | 9 yrs ago

About Healios K.K.

Healios K.K. aims to commercialize the world's first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.

Headquarters Location

Tokyo,

Japan

+81-3-3544-8730

Missing: Healios K.K.'s Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Healios K.K.'s Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Healios K.K.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Healios K.K. is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Healios K.K. Patents

Healios K.K. has filed 7 patents.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/29/2017

12/13/2022

Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Rare diseases, Visual system

Grant

Application Date

6/29/2017

Grant Date

12/13/2022

Title

Related Topics

Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Rare diseases, Visual system

Status

Grant

Latest Healios K.K. News

Japan’s Healios advances its iPSC-derived gene engineered killer cells toward the clinic

Aug 30, 2022

Aug. 30, 2022 Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.

Healios K.K. Frequently Asked Questions (FAQ)

  • Where is Healios K.K.'s headquarters?

    Healios K.K.'s headquarters is located at Tokyo.

  • What is Healios K.K.'s latest funding round?

    Healios K.K.'s latest funding round is Unattributed.

  • How much did Healios K.K. raise?

    Healios K.K. raised a total of $30.6M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.